Yongdong Jin

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial

Ying–Hong Shi, Guohong Han, Jian Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2025 · 39 citations

Medicine, Oncology, Pharmacology +10

Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers

Zhenghang Wang, Siyuan Cheng, Yanhong Yao et al. · Cancer Immunology Immunotherapy · 2024 · 15 citations · Full text

Medicine, Immunology, Oncology +17

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study

Shukui Qin, Shanzhi Gu, Stephen L. Chan et al. · The Lancet Oncology · 2025 · 13 citations

Medicine, Oncology, Pharmacology +11